PT - JOURNAL ARTICLE AU - Dai, Yuan AU - Zhang, Lingli AU - Yu, Juehua AU - Zhou, Xin AU - He, Hua AU - Ji, Yiting AU - Wang, Kai AU - Du, Xiujuan AU - Liu, Xin AU - Tang, Yun AU - Deng, Shining AU - Langley, Christelle AU - Li, Wei-Guang AU - Zhang, Jun AU - Feng, Jianfeng AU - Sahakian, Barbara J AU - Luo, Qiang AU - Li, Fei TI - Improved symptoms following bumetanide treatment in children aged 3 to 6 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial AID - 10.1101/2020.09.18.20197640 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.18.20197640 4099 - http://medrxiv.org/content/early/2020/12/19/2020.09.18.20197640.short 4100 - http://medrxiv.org/content/early/2020/12/19/2020.09.18.20197640.full AB - With the drug therapy for the core symptoms of autism spectrum disorder (ASD) currently limited, here we reported a randomised, double-blind, placebo-controlled trial to investigate the efficacy, safety, and potential neural mechanism of bumetanide in children with ASD aged 3 to 6 years old. There were 120 children entered into the study and randomly assigned to either 0.5mg bumetanide or placebo. In the final sample, 119 received at least one dose of bumetanide (59 children) or placebo (60 children). The primary outcome was the score reduction of Childhood Autism Rating Scale (CARS) and the secondary outcomes were the score of Clinical Global Impressions Scale (CGI) -Global Improvement (CGI-I) at 3 months and the change from baseline to 3-month in Autism Diagnostic Observation Schedule (ADOS). Magnetic resonance spectroscopy (MRS) was used to measure γ-aminobutyric acid (GABA) and glutamate neurotransmitter concentrations in the insular cortex (IC) before and after the treatment. As compared with the placebo, bumetanide treatment was significantly better in reducing severity. No patient withdrew from the trial due to adverse events. The superiority of bumetanide to placebo in reducing insular GABA, measured using MRS, was demonstrated. The clinical improvement was associated with the decrease in insular GABA in the bumetanide group. In conclusion, this trial in a large group of young children with predominantly moderate and severe ASD demonstrated that bumetanide is safe and effective in improving the core symptoms of ASD. However, the clinical significance remains uncertain and future multi-center clinical trials are required to replicate these findings and confirm the clinical significance using a variety of outcome measures.Competing Interest StatementProf. Barbara J. Sahakian consults for Cambridge Cognition, Greenfield BioVentures and Cassava Sciences. All other authors declare no conflict of interest.Clinical TrialNCT03156153Funding StatementThis project was funded by the Shanghai Municipal Commission of Health and Family Planning (No.2017ZZ02026, No. 2018BR33, No.2017EKHWYX-02 and No.GDEK201709), Shanghai Shenkang Hospital Development Center (No.16CR2025B), Shanghai Municipal Education Commission (No.20152234), National Natural Science Foundation of China (No. 81571031, No. 81761128035, No.81930095, No. 81873909, No.81701334, No. 81703249，No.82001771 and No. 31860306), Shanghai Committee of Science and Technology (No.17XD1403200, No.17ZR1444400, No.19410713500, No.18DZ2313505), Xinhua Hospital of Shanghai Jiao Tong University School of Medicine (2018YJRC03, Talent introduction-014 and Top talent-201603), National Human Genetic Resources Sharing Service Platform (2005DKA21300), the National Key Research and Development Program of China (2018YFC0910503), 111 Project (No.B18015), the Shanghai Municipal Science and Technology Major Project (No.2018SHZDZX01), Guangdong Key Project in "Development of new tools for diagnosis and treatment of Autism" (2018B030335001), Science and Technology Department of Yunnan Province (202001AV070010) and ZJ Lab.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki and was reviewed and approved by the Ethics Committee of Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine (XHEC-C-2016-103). Parents or legal guardians of all participants provided written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTo facilitate reproducibility of our analysis, we have provided all data analytic code on GitHub in the following webpage: https://github.com/qluo2018/RCT.